Chiesi Acquires KalVista: A Major Move in the Rare Disease Market
Summary
Chiesi Group, a family-owned Italian drugmaker, has announced plans to acquire KalVista Pharmaceuticals for $1.9 billion in order to obtain the company’s newly launched pill for hereditary angioedema, a rare swelling disorder. This acquisition is expected to significantly contribute to Chiesi’s 2030 revenue target and reflects the growing interest in finding better treatments for this genetic condition.
Access impact
The acquisition of KalVista by Chiesi will have significant pricing, reimbursement, and HTA implications for the rare disease market. The approval of KalVista’s oral, on-demand treatment for hereditary angioedema has already shown promising results, with almost $50 million in sales in its first year. This acquisition will also strengthen Chiesi’s rare disease unit and expand its commercial infrastructure in the U.S., potentially opening up access to this treatment for more patients.
Top-3 domain lens
Clinical Effectiveness
The approval of KalVista’s oral treatment for hereditary angioedema provides a new, more convenient option for patients compared to traditional injections. This will likely have a positive impact on the clinical effectiveness of treatment for this condition.
Cost-Effectiveness
With the potential for the on-demand market for hereditary angioedema to reach $1.8 billion, this acquisition highlights the cost-effectiveness of KalVista’s treatment compared to other options. It also reflects the strong strategic interest in the oral HAE space, potentially leading to further cost-effective options in the future.
Budget Impact and Resources
The acquisition of KalVista by Chiesi is a major move in the rare disease market, securing an exit for investors and potentially leading to more interest in similar companies such as Pharvaris and BioCryst Pharmaceuticals. This could lead to a budget impact and allocation of resources towards further research and development in this area.
Hashtags
#MarketAccessRiskAssessment #Pricing #Reimbursement #MarketAccess #MARArating #Company #Drug #RegulatoryAgency
CTA
Explore 350+ independent assessments: https://mararating.com/mara-ratings-list
Source
source: https://www.biopharmadive.com/news/chiesi-kalvista-deal-acquire-hereditary-angioedema-ekterly/818798/